{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:20:04Z","timestamp":1780633204453,"version":"3.54.1"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:p>The <jats:italic toggle=\"yes\">PLEKHH2::ALK<\/jats:italic> fusion is a rarely reported gene fusion identified predominantly in lung adenocarcinomas. Tumors with this fusion have been reported to be of durable response to ALK inhibitors. We herein present the case of a 21-year-old woman with a histomorphologically heterogenous mesenchymal neoplasm of the pelvis, expressing both s100 and CD34, with subsequently identified <jats:italic toggle=\"yes\">PLEKHH2::ALK<\/jats:italic> fusion. To our knowledge, only a single mesenchymal neoplasm with this gene fusion has been previously reported. We propose that this tumor represents one with a novel <jats:italic toggle=\"yes\">ALK<\/jats:italic> fusion in the emerging family of s100 and CD34 expressing mesenchymal neoplasms with oncogenic kinase alterations akin to <jats:italic toggle=\"yes\">NTRK<\/jats:italic>-rearranged mesenchymal neoplasms, rather than inflammatory myofibroblastic tumor. Importantly, this tumor demonstrated a significant response to the ALK inhibitor brigatinib.<\/jats:p>","DOI":"10.1097\/pas.0000000000001887","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T09:19:16Z","timestamp":1647335956000},"page":"1309-1313","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["S100 and CD34 Expressing Mesenchymal Neoplasm With Rare PLEKHH2::ALK Fusion and Response to ALK Inhibition"],"prefix":"10.1097","volume":"46","author":[{"given":"Joseph D.","family":"Coppock","sequence":"first","affiliation":[{"name":"Departments of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Schneider","sequence":"additional","affiliation":[{"name":"Hematology & Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea F.","family":"Surrey","sequence":"additional","affiliation":[{"name":"Department of Pathology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgos C.","family":"Karakousis","sequence":"additional","affiliation":[{"name":"Surgery, Hospital of the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Maki","sequence":"additional","affiliation":[{"name":"Hematology & Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumarasen","family":"Cooper","sequence":"additional","affiliation":[{"name":"Departments of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/gcc.22671","article-title":"A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1\/2 genes","volume":"57","author":"Suurmeijer","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/his.14603","article-title":"ALK rearrangements in infantile fibrosarcoma-like spindle cell tumours of soft tissue and kidney","volume":"80","author":"Tan","year":"2021","journal-title":"Histopathology"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41379-021-00830-w","article-title":"Superficial ALK-rearranged myxoid spindle cell neoplasm: a cutaneous soft tissue tumor with distinctive morphology and immunophenotypic profile","volume":"34","author":"Dermawan","year":"2021","journal-title":"Mod Pathol"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/cup.13926","article-title":"Spindle cell tumor with CD34 and S100 co-expression and distinctive stromal and perivascular hyalinization showing EML4-ALK fusion","volume":"48","author":"Abs","year":"2021","journal-title":"J Cutan Pathol"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/gcc.22917","article-title":"Spindle cell neoplasm with EML4-ALK gene fusion presenting as an intraosseous vertebral mass","volume":"60","author":"Mantilla","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/gcc.22844","article-title":"Novel PPP1CB-ALK fusion in spindle cell tumor defined by S100 and CD34 coexpression and distinctive stromal and perivascular hyalinization","volume":"59","author":"Lopez-Nunez","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/gcc.22877","article-title":"Soft tissue tumors characterized by a wide spectrum of kinase fusions share a lipofibromatosis-like neural tumor pattern","volume":"59","author":"Kao","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"e23554","DOI":"10.1200\/JCO.2021.39.15_suppl.e23554","article-title":"Loss of 5\u2032ALK leads to better response to crizotinib in sarcomas with ALK rearrangement","volume":"39","author":"Li","year":"2021","journal-title":"J Clin Oncol"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.lungcan.2019.11.002","article-title":"PLEKHM2-ALK: a novel fusion in small-cell lung cancer and durable response to ALK inhibitors","volume":"139","author":"Li","year":"2020","journal-title":"Lung Cancer"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.cllc.2020.07.017","article-title":"PLEKHH2-ALK: a novel in-frame fusion with durable response to alectinib: utilizing RNA sequencing in search for hidden gene fusions susceptible to targeted therapy","volume":"22","author":"Nagasaka","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1056\/NEJMoa1007056","article-title":"Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor","volume":"363","author":"Butrynski","year":"2010","journal-title":"N Engl J Med"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001887","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T21:04:03Z","timestamp":1749416643000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001887","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,15]]}}}